MedTrace Logo

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

NCT05798546 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-04-04

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety of Neo-T in the treatment of advanced solid tumors.

The secondary objective of this study is to evaluate preliminarily the effect of Neo-T in the treatment of advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

Neo-T

Patients will recive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.

DRUG

Cyclophosphamide

Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.

DRUG

Fludarabine

Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.

DRUG

Interleukin-2

500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • BGI, China

    lead OTHER

Principal Investigators

  • Jing Chen, Doctor · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-28
Primary Completion
2023-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05798546 on ClinicalTrials.gov